Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
Pemov A, Hansen NF, Sindiri S, Patidar R, Higham CS, Dombi E, Miettinen MM, Fetsch P, Brems H, Chandrasekharappa SC, Jones K, Zhu B, Wei JS; National Intramural Sequencing Center (NISC) Comparative Sequencing Program; National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG) Cancer Genomics Research Laboratory; Mullikin JC, Wallace MR, Khan J, Legius E, Widemann BC, Stewart DR.
Pemov A, et al. Among authors: wei js.
Neuro Oncol. 2019 Aug 5;21(8):981-992. doi: 10.1093/neuonc/noz028.
Neuro Oncol. 2019.
PMID: 30722027
Free PMC article.